Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-06-14T16:28:03.640Z Has data issue: false hasContentIssue false

Sensorineural hearing loss following induction chemotherapy plus concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma

Published online by Cambridge University Press:  26 June 2015

V Atchariyasathian*
Department of Otolaryngology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
K Pruegsanusak
Department of Otolaryngology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
S Wongsriwattanakul
Department of Otolaryngology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
Address for correspondence: Dr Viraporn Atchariyasathian, Department of Otolaryngology, Prince of Songkla University, 15 Karnjanavanit Road, Songkhla, Thailand90110 Fax: +66 74 429 620 E-mail:



To compare the incidence of sensorineural hearing loss between those treated with docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by carboplatin concurrent chemoradiotherapy and those treated with conventional concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma.


Serial pure tone audiometry was conducted in 36 nasopharyngeal carcinoma patients who were randomised into 2 groups. The first group received docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by carboplatin concurrent chemoradiotherapy. The second group received conventional concurrent chemoradiotherapy.


The incidence of sensorineural hearing loss at speech frequency in the first group was 10 per cent and in the second group was 50 per cent (p = 0.0027). Bone conduction thresholds were significantly increased after completion of the treatment at 2–4 kHz in the first group and at all frequencies in the second group.


The docetaxel, cisplatin and 5-fluorouracil induction chemotherapy regimen followed by concurrent chemoradiotherapy was associated with a lower incidence of sensorineural hearing loss than conventional concurrent chemoradiotherapy. This regimen may be the preferred choice of treatment for hearing preservation.

Main Articles
Copyright © JLO (1984) Limited 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


1Al-Sarraf, M, LeBlanc, M, Giri, PG, Fu, KK, Cooper, J, Voung, T et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998;16:1310–17CrossRefGoogle ScholarPubMed
2Lin, JC, Jan, JS, Hsu, CY, Liang, WM, Jiang, RS, Wang, WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631–7CrossRefGoogle ScholarPubMed
3Chan, AT, Leung, SF, Ngan, RK, Teo, PM, Lau, WH, Kwan, WH et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536–9CrossRefGoogle ScholarPubMed
4Zhang, L, Zhao, C, Peng, PJ, Lu, LX, Huang, PY, Han, F et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005;23:8461–8CrossRefGoogle ScholarPubMed
5Lee, AW, Lau, WH, Tung, SY, Chau, DT, Chappell, R, Xu, L et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005;23:6966–75CrossRefGoogle Scholar
6Musial-Bright, L, Fengler, R, Henze, G, Hernáiz, DP. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv Syst 2011;27:407–13CrossRefGoogle ScholarPubMed
7Bertolini, P, Lassalle, M, Mercier, G, Raquin, MA, Izzi, G, Corradini, N et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004;26:649–55CrossRefGoogle ScholarPubMed
8Dean, JB, Hayashi, SS, Albert, CM, King, AA, Karzon, R, Hayashi, RJ. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol 2008;30:130–4CrossRefGoogle ScholarPubMed
9Pearson, SE, Meyer, AC, Adams, GL, Ondrey, FG. Decreased hearing after combined modality therapy for head and neck cancer. Am J Otolaryngol 2006;27:7680CrossRefGoogle ScholarPubMed
10Chen, WC, Jackson, A, Budnick, AS, Pfister, DG, Kraus, DH, Hunt, MA et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 2006;106:820–9CrossRefGoogle ScholarPubMed
11Sumitsawan, Y, Vaseenon, V, Hanprasertpong, J, Roongrotwattanasiri, K, Chitapanarux, I, Isaradisaikul, S. High frequency hearing loss following treatment for nasopharyngeal carcinoma. J Med Assoc Thai 2010;93:324–9Google ScholarPubMed
12Oh, YT, Kim, CH, Choi, JH, Kang, SH, Chun, M. Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma. Radiother Oncol 2004;72:7982CrossRefGoogle ScholarPubMed
13Ekenel, M, Keskin, S, Basaran, M, Ozdemir, C, Meral, R, Altun, M et al. Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma. Oral Oncol 2011;47:660–4CrossRefGoogle ScholarPubMed
14Kong, L, Zhang, YW, Hu, CS, Guo, Y. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma. Chin J Cancer 2010;29:551–5CrossRefGoogle ScholarPubMed
15NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Head and Neck Cancers, Version 2.2013. In: [3 June 2015]Google Scholar
16Bossi, P, Orlandi, E, Bergamini, C, Locati, LD, Granata, R, Mirabile, A et al. Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. Ann Oncol 2011;22:2495–500CrossRefGoogle ScholarPubMed
17Bardet, E, Bourhis, J, Cals, L, Fayette, J, Guigay, J, Hans, S et al. Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy [in French]. Bull Cancer 2009;96:1013–28Google Scholar
18Bae, WK, Hwang, JE, Shim, HJ, Cho, SH, Lee, JK, Lim, SC et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother Pharmacol 2010;65:589–95CrossRefGoogle ScholarPubMed
19Guo, L, Lin, HX, Xu, M, Chen, QY, Wang, CT, Huang, PY. Phase I study of TPF neoadjuvant chemotherapy followed by radical radiotherapy in advanced nasopharyngeal carcinoma. Chin J Cancer 2010;29:136–9CrossRefGoogle ScholarPubMed
20Atas, A, Agca, O, Sarac, S. Investigation of ototoxic effects of Taxol on a mice model. Int J Pediatr Otorhinolaryngol 2006;70:779–84CrossRefGoogle ScholarPubMed
21Ridwelski, K, Gebauer, T, Fahlke, J, Kroning, H, Kettner, E, Meyer, F. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:4755CrossRefGoogle ScholarPubMed
22Sarafraz, M, Ahmadi, K. Paraclinical evaluation of side-effects of Taxanes on auditory system. Acta Otorhinolaryngol Ital 2008;28:239–42Google ScholarPubMed
23Grau, C, Overgaard, J. Postirradiation sensorineural hearing loss: a common but ignored late radiation complication. Int J Radiat Oncol Biol Phys 1996;36:515–17CrossRefGoogle ScholarPubMed